natgillin/translations-raw huggingface dataset:
clinically relevant drug-drug interaction is expected.
Glede na presnovno pot entekavirja ni pričakovati klinično pomembnih interakcij med zdraviloma.
clinically relevant heart failure with reduced left-ventricular ejection fraction
klinično releventnim srčnim popuščanjem z zmanjšanim iztisnim deležem levega prekata,
Clinically relevant improvement in these studies was defined a priori as at least 4-point improvement on the ADAS-Cog, improvement on the CIBIC-Plus, or at least a 10 % improvement on the PDS.
V teh študijah je bilo klinično pomembno izboljšanje vnaprej opredeljeno kot izboljšanje rezultata ADAS-Cog za vsaj 4 točke, izboljšanje rezultata CIBIC-Plus, ali vsaj 10-odstotno izboljšanje rezultata PDS.
Clinically relevant improvement in these studies was defined a priori as at least 4-point improvement on the ADAS-Cog, improvement on the CIBIC-Plus, or at least a 10% improvement on the PDS.
Klinično pomembno izboljšanje v teh študijah je bilo pri ADAS-Cog opredeljeno kot izboljšanje za vsaj 4 točke, pri CIBIC- Plus kot izboljšanje, pri PDS pa vsaj kot desetodstotno izboljšanje.
Clinically relevant non-major
Klinično pomembne majhne krvavitve
Clinically relevant or severe abnormalities of routine haematological or biochemistry laboratory values are presented in Table 3.
V preglednici 3 so prikazane klinično pomembne ali hude nepravilnosti rutinskih hematoloških ali biokemijskih laboratorijskih izvidov.
Clinically relevant plasma levels are largely determined by the time for the sufentanil plasma concentration to drop from Cmax to 50 % of Cmax after discontinuation of dosing (context sensitive half- time or CST½) rather than by the terminal half-life.
Klinično pomembne plazemske koncentracije so v veliki meri odvisne od časa, potrebnega za znižanje koncentracije sufentanila v plazmi z vrednosti Cmax na 50% vrednosti Cmax po prekinitvi odmerjanja (na kontekst občutljiv razpolovni čas CST½), ne pa od končnega razpolovnega časa.
Clinically relevant reactions (including Grade ≥3) associated with antiangiogenic therapy observed in ramucirumab-treated patients across clinical studies were: gastrointestinal perforations, infusion- related reactions and proteinuria (see sections 4.2 and 4.4).
Klinično pomembne reakcije (vključno z razredom ≥ 3), ki so povezane z antiangiogenim zdravljenjem in so jih opazili pri bolnikih, zdravljenih z ramucirumabom v kliničnih študijah, so: gastrointestinalne perforacije,reakcije, povezane z infuzijo in proteinurija (glejte poglavji 4.2 in 4.4).
Clinically relevant toxicities with respect to the elderly and those patients with Eastern Cooperative Oncology Group (ECOG) performance status score 2 (ECOG PS2) were similar to the overall population in patients receiving necitumumab plus chemotherapy consisting of gemcitabine and cisplatin.
Klinično pomembne toksičnosti pri starejših in bolnikih z oceno stanja zmogljivosti 2 po ECOG (Eastern Cooperative Oncology Group) (ECOG PS2) so bile podobne kot v celokupni populaciji bolnikov, ki so prejemali necitumumab in kemoterapijo, sestavljeno iz gemcitabina in cisplatina.
Clinically relevant toxicity that was reported in ≥ 1 % and ≤ 5 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: AST increase, ALT increase, infection, febrile neutropenia, renal failure, pyrexia, dehydration, conjunctivitis, and creatinine clearance decrease.
Klinično pomembne toksičnosti, o katerih so poročali pri > 1 % in < 5 % bolnikov, ki so jih naključno dodelili v skupino, ki je prejemala pemetreksed, vključujejo: povišanje AST, povišanje ALT, okužbo, febrilno nevtropenijo, odpoved ledvic, pireksijo, dehidracijo, konjuktivitis in znižanje očistka kreatinina.
Clinically relevant toxicity that was reported in ≥ 1% and ≤ 5 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: AST increase, ALT increase, infection, febrile neutropenia, renal failure, pyrexia, dehydration, conjunctivitis, and creatinine clearance decrease.
Klinično pomembne toksičnosti, o katerih so poročali pri > 1 % in < 5 % bolnikov, ki so jih naključno dodelili v skupino, ki je prejemala pemetreksed, vključujejo: povišanje AST, povišanje ALT, okužbo, febrilno nevtropenijo, odpoved ledvic, pireksijo, dehidracijo, konjuktivitis in znižanje očistka kreatinina.
Clinically relevant toxicity that was reported in ≥ 1% and ≤ 5% of the patients that were randomly assigned to receive cisplatin and pemetrexed include: AST increase, ALT increase, infection, febrile neutropenia, renal failure, pyrexia, dehydration, conjunctivitis, and creatinine clearance decrease.
Klinično pomembne toksičnosti, o katerih so poročali pri > 1 % in < 5 % bolnikov, ki so jih naključno dodelili v skupino, ki je prejemala pemetreksed, vključujejo: povišanje AST, povišanje ALT, okužbo, febrilno nevtropenijo, odpoved ledvic, pireksijo, dehidracijo, konjuktivitis in znižanje očistka kreatinina.
Clinically relevant toxicity that was reported in ≥ 1% and ≤ 5% of the patients that were randomly assigned to receive cisplatin and pemetrexed include: AST increase, ALT increase, infection, febrile neutropenia, renal failure, pyrexia, dehydration, conjunctivitis, and creatinine clearance decrease.
Klinično pomembne toksičnosti, o katerih so poročali pri ≥ 1 % in ≤ 5 % bolnikov, ki so jih naključno dodelili v skupino, ki je prejemala pemetreksed, vključujejo: povišanje AST, povišanje ALT, okužbo, febrilno nevtropenijo, odpoved ledvic, pireksijo, dehidracijo, konjuktivitis in znižan očistek kreatinina.
Clinically significant active bleeding.
Klinično pomembna aktivna krvavitev.
Clinically significant adverse reactions observed in clinical trials included hypotension and ventricular arrhythmia. (see sections 4.4 Hypotension, Congestive Heart Failure).
Med klinično pomembnimi neželenimi učinki v kliničnih preskušanjih so bile hipotenzija in prekatne motnje srčnega ritma (glejte poglavji 4.4 Hipotenzija, Kongestivno srčno popuščanje).
Clinically significant bladder outflow obstruction at risk of urinary retention (e.g. clinically significant prostate enlargement due to benign prostatic hyperplasia, see section 4.3)
klinično pomembno obstrukcijo mehurja s tveganjem za retencijo urina (npr. klinično pomembno povečanje prostate zaradi benigne hiperplazije prostate, glejte poglavje 4.3);
Clinically significant disorders of the gastrointestinal, cardiovascular, respiratory, endocrine (including diabetes, Cushing’s disease, Addison’s disease, Peutz-Jeghers syndrome), neurological (including seizures) and haematological (especially anaemia) systems have not been evaluated.
Klinično pomembne gastrointestinalne, kardiovaskularne, respiratorne, endokrine (vključno s sladkorno boleznijo, Cushingovo boleznijo, Addisonovo boleznijo, Peutz-Jeghersovim sindromom), nevrološke (vključno z epileptičnimi napadi) in hematološke motnje (predvsem anemije) niso bile ocenjene.
clinically significant hepatic impairment concomitant or planned administration of another parenteral glycoprotein (GP) IIb/IIIa inhibitor
klinično pomembno jetrno okvaro; sočasno ali predvideno uporabo kakega drugega parenteralnega zaviralca glikoproteina (GP) IIb/IIIa.
Clinically significant hypercalcaemia has been reported in XGEVA-treated patients with growing skeletons weeks to months following treatment discontinuation.
Pri bolnikih s še razvijajočim se skeletom, ki so bili zdravljeni z zdravilom XGEVA, so poročali o klinično pomembni hiperkalciemiji še tedne do mesece po prenehanju zdravljenja.
Clinically significant hypotension or bradycardia should be treated as described in section 4.4.
Klinično pomembno hipotenzijo ali bradikardijo je treba zdraviti, kakor je opisano v poglavju 4.4.
Clinically significant interactions are not expected since the NRTIs are metabolised via a different route than efavirenz and would be
Klinično pomembnih interakcij ni pričakovati, saj se
Clinically significant interactions are not expected since the NRTIs are metabolised via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways.
NRTI presnavljajo po drugi poti kot efavirenz in ni verjetno, da bi prišlo do kompeticije za iste presnovne encime in poti izločanja.
Clinically significant interactions have not been observed between nelfinavir and nucleoside analogues.
Klinično pomembnih medsebojnih delovanj med nelfinavirjem in nukleozidnimi analogi (posebno kombinacije zidovudin in lavimudin, stavudin ter stavudin in didanozin) niso opazili.
Clinically significant medicinal product interactions with Epclusa mediated by P-gp, BCRP, OATP, or CYP450 inhibitors are not expected; Epclusa may be co-administered with P-gp, BCRP, OATP and CYP inhibitors.
Klinično pomembnih medsebojnih delovanj z zdravilom Epclusa, pri katerih bi posredovali zaviralci P-gp, BCRP, OATP ali CYP450, se ne pričakuje; zdravilo Epclusa se lahko uporablja sočasno z zaviralci P-gp, BCRP, OATP in CYP.
Clinically significant PK interactions between vismodegib and CYP450 inhibitors are not expected.
Klinično pomembnega farmakokinetičnega medsebojnega delovanja med vismodegibom in zaviralci CYP450 ni pričakovati.
clinically significant.
klinično pomembni.
clinically significant.
za klinično pomembni.
Clinically the following substances have been shown to decrease tacrolimus blood levels:
Klinično je ugotovljeno, da koncentracijo takrolimusa v krvi znižujejo naslednje snovi:
Clinically the following substances have been shown to increase tacrolimus blood levels:
Klinično je ugotovljeno, da koncentracijo takrolimusa v krvi zvišujejo naslednje snovi:
Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AKs) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.
Klinično tipičnih nehiperkeratotičnih, nehipertrofičnih aktiničnih keratoz (AK) na obrazu in lasišču pri odraslih bolnikih, ko je velikost ali število lezij tolikšno, da ni uspešna ali/in sprejemljiva krioterapija in so drugi načini zdravljenja kontraindicirani ali pa so manj primerni.
Clinically validated phenotypic interpretation systems may be used in association with the genotypic data to estimate the activity of amprenavir / ritonavir or fosamprenavir / ritonavir in patients with PI- resistant isolates.
Za ocenjevanje delovanja amprenavirja /ritonavirja ali fosamprenavirja /ritonavirja pri bolnikih z izolati, odpornimi na zaviralce proteaz, se lahko uporabijo klinično ovrednoteni fenotipski interpretacijski sistemi v kombinaciji z genotipskimi podatki.
Clinically, the following substances have been shown to increase tacrolimus blood levels:
Klinično je ugotovljeno, da koncentracijo takrolimusa v krvi zvišujejo naslednje snovi:
clitoral engorgement
nabrekanje klitorisa
CLL and FL are types of cancer that affect white blood cells called “B-lymphocytes”.
KLL in FL sta dve vrsti raka, ki prizadeneta vrsto belih krvnih celic, imenovanih limfociti B. Prizadeti limfociti B se množijo prehitro in živijo predolgo.
CLL is a cancer of B-lymphocytes, a type of white blood cells.
KLL je rak limfocitov B, ki so vrsta belih krvnih celic.
CLL only – Cycle 1
Samo za 1. ciklus KLL
CLL only – Cycle 1
Samo za 1. ciklus pri KLL
CLL/WM dose modification after recovery
Prilagoditev odmerjanja po okrevanju pri KLL/WM
Clofarabine AUC0-24 hours by baseline estimated creatinine clearance in patients aged between 2 to 19 years old with relapsed or refractory ALL or AML (n = 11 / n = 12) following administration of multiple doses of clofarabine by intravenous infusion
AUC0–24 ur klofarabina po ocenjenem izhodiščnem kreatininskem očistku pri bolnikih, starih 2 do 19 let s ponovljeno ali neodzivno ALL ali AML (n = 11/n = 12) po intravenskem infundiranju več odmerkov klofarabina
Clofarabine is an ‘analogue’ of adenine, which is part of the fundamental genetic material of cells (DNA and RNA).
Klofarabin je analog adenina, ki je del osnovnega genetskega materiala celic (DNK in RNK).
Clofarabine must first diffuse or be transported into target cells where it is sequentially phosphorylated to the mono- and bi-phosphate by intracellular kinases, and then finally to the active conjugate, clofarabine 5’-triphosphate.
Klofarabin mora najprej difundirati ali se transportirati v ciljne celice, kjer ga znotrajcelične kinaze zaporedno fosforilirajo v mono- in difosfate, in na koncu v aktivni konjugat, klofarabin 5’-trifosfat.
clogging of a very small blood vessel(s) in the kidney,
trdki v zelo majhni krvni žili (ali žilah) v ledvicah,
Clomicalm 20 mg tablets for dogs Clomipramine hydrochloride
Clomicalm 20 mg tablete za pse
Clomicalm 20 mg tablets for dogs Clomipramine hydrochloride
Clomicalm 20 mg tablete za pse Clomipramini hydrochloridum
Clomicalm 5 mg tablets for dogs Clomipramine hydrochloride
Clomicalm 5 mg tablete za pse
Clomicalm 5 mg tablets for dogs Clomipramine hydrochloride
Clomicalm 5 mg tablete za pse Clomipramini hydrochloridum
Clomicalm 80 mg tablets for dogs Clomipramine hydrochloride
Clomicalm 80 mg tablete za pse
Clomicalm 80 mg tablets for dogs Clomipramine hydrochloride
Clomicalm 80 mg tablete za pse Clomipramini hydrochloridum
Clomicalm is administered twice daily at a dose of 1-2 mg/kg clomipramine to give a total daily dose of 2 - 4 mg/kg according to the following table:
Clomicalm se daje dvakrat dnevno v odmerku 1-2 mg/kg telesne mase.
Clomicalm is administered twice daily at a dose of 1-2 mg/kg clomipramine to give a total daily dose of 2-4 mg/kg according to the following table:
Clomicalm se daje dvakrat dnevno v odmerku 1-2 mg/kg telesne mase.
Clomicalm is may be given orally with or without food.
Clomicalm se daje peroralno, lahko tudi s hrano.
Clomicalm may be given with or without food.
Clomicalm se lahko daje tudi skupaj s hrano.
Clomicalm may increase the effects of the anti-arrhythmic drug quinidine, anticholinergic agents (e.g. atropine), other CNS active drugs (e.g. barbiturates, benzodiazepines, general anaesthetics, neuroleptics), sympathomimetics (e.g. adrenaline) and coumarine derivatives.
Clomicalm lahko potencira učinkovanje antiaritmikov, cinidonov, antiholinergikov (atropin), drugih zdravil, ki delujejo na CŽS (barbiturati, benzodiazepini, splošni anestetiki, neuroleptiki), simpatikomimetikov (adrenalin) in kumarinskih derivatov.
Clomicalm may potentiate the effects of the anti-arrhythmic drug quinidine, anticholinergic agents (e.g. atropine), other CNS active drugs (e.g. barbiturates, benzodiazepines, general anaesthetics, neuroleptics), sympathomimetics (e.g. adrenaline) and coumarin derivatives.
Clomicalm lahko potencira učinkovanje antiaritmikov, cinidonov, antiholinergikov (atropin), drugih zdravil, ki delujejo na CŽS (barbiturati, benzodiazepini, splošni anestetiki, neuroleptiki), simpatikomimetikov (adrenalin) in kumarinskih derivatov.
Clomicalm may very rarely cause vomiting, changes in appetite, lethargy or an elevation in liver enzymes, which is reversible when the product is discontinued.
Clomicalm lahko povzroči bruhanje, spremembo apetita ali letargijo.
Clomicalm should be used under veterinary supervision.
Clomicalm uporabljajte pod nadzorom veterinarja.
Clomicalm should only be given in combination with behavioural therapy.
Zdravilo Clomicalm se lahko daje samo v kombinaciji z vedenjsko terapijo.
Clomipramine and its metabolites are rapidly distributed in the body in mice, rabbits, and rats with high concentrations being achieved in organs and tissues (including the lungs, heart and brain) and low concentrations remaining in the blood.
Klomipramin in njegovi metaboliti se pri miših, zajcih in podganah hitro distribuirajo po organizmu in dosežejo visoke koncentracije v tkivih in organih (vključno v pljučih, srcu in možganih), nizke pa v krvi.
Clomipramine has a broad-spectrum of action in blocking the neuronal reuptake of both serotonin (5- HT) and noradrenaline.
Klomipramin ima širok spekter učinkovanja, saj blokira delovanje adrenergičnih neuronov- serotonina (5-HT) in noradrenalina.
Clomipramine hydrochloride
Clomipramini hydrochloridum
Clomipramine hydrochloride 20 mg (equivalent to 17.9 mg Clomipramine)
Klomipraminijev klorid 20.00 mg
Clomipramine hydrochloride 5 mg (equivalent to 4.5 mg Clomipramine)
Klomipraminijev klorid 5.00 mg
Clomipramine hydrochloride 80 mg (equivalent to 71.7 mg Clomipramine)
Klomipraminijev klorid 80.00 mg
Clomipramine hydrochloride mg (equivalent to 71.7 mg Clomipramine)
Klomipraminijev klorid 80.00 mg
Clomipramine is extensively bound to plasma proteins (>97 %) in dogs.
Klomipramin se dobro veže na plazemske beljakovine ( >97%).
clonidine (used to treat high blood pressure), lithium salts (used to treat psychiatric disorders).
klonidin (uporablja se za zdravljenje visokega krvnega tlaka) litijeve soli (uporabljajo se za zdravljenje psihiatričnih motenj)
clonidine (used to treat high blood pressure), lithium salts (used to treat psychiatric disorders).
klonidin (uporablja se za zdravljenje visokega krvnega tlaka) litijeve soli (uporabljajo se za zdravljenje psihiatričnih motenj).
clonidine (used to treat high blood pressure), lithium salts (used to treat psychiatric disorders).
klonidin (uporablja se za zdravljenje visokega krvnega tlaka), litijeve soli (uporabljajo se za zdravljenje psihiatričnih motenj).
clonidine (used to treat high blood pressure), lithium salts (used to treat psychiatric disorders).
klonidin uporablja se za zdravljenje visokega krvnega tlaka), litijeve soli (uporabljajo se za zdravljenje psihiatričnih motenj).
clonidine (used to treat high blood pressure), lithium salts (used to treat psychiatric disorders).
klonidin(uporablja se za zdravljenje visokega krvnega tlaka), litijeve soli (uporabljajo se za zdravljenje psihiatričnih motenj).
clonidine (used to treat high blood pressure), lithium salts (usedto treat psychiatric disorders).
klonidin (uporablja se za zdravljenje visokega krvnega tlaka), litijeve soli (uporabljajo se za zdravljenje psihiatričnih motenj).
Clonidine, guanfacine, used to treat hypertension.
klonidin, guanfacin, ki se uporabljata za zdravljenje zvišanega krvnega tlaka,
Clonus Dysgeusia Hypoaesthesia Hypogeusia
klonus dizgevzija
Clopidogre 1A Pharma 75 mg film-coated tablets Clopidogrel
Klopidogrel 1A Pharma 75 mg filmsko obložene tablete klopidogrel
Clopidogre HEXAL 75 mg film-coated tablets Clopidogrel
Klopidogrel HEXAL 75 mg filmsko obložene tablete klopidogrel
Clopidogrel
KU lopidogrel
Clopidogrel
NSAR klopidogrel
Clopidogrel
UKlopidogrel
Clopidogrel
UKlopidogrelU
Clopidogrel (% patients with event) N=9291
Klopidogrel (% bolnikov z dogodkom) n = 9291
Clopidogrel (N=12542)
Klopidogrel (N = 12.542)
Clopidogrel (N=5527)
Klopidogrel (N = 5.527)
Clopidogrel (prevents blood clots)
klopidogrel (zdravilo, ki preprečuje nastajanje krvnih strdkov),
Clopidogrel (prevents blood clots).
klopidogrel (zdravilo, ki preprečuje nastajanje krvnih strdkov),
Clopidogrel 1A Pharma 75 mg
Klopidogrel 1A Pharma 75 mg
Clopidogrel 1A Pharma 75 mg film-coated tablets
Klopidogrel 1A Pharma 75 mg filmsko obložene tablete
Clopidogrel 1A Pharma can be given to the following groups of patients: patients who have recently had a myocardial infarction (heart attack).
Zdravilo Clopidogrel 1A Pharma se lahko daje naslednjim skupinam bolnikov: bolnikom, ki so nedavno doživeli miokardni infarkt (srčni napad).
Clopidogrel 1A Pharma can be started between a few days and 35 days after the attack; patients who have had a recent ischaemic stroke (stroke caused by failure of the blood supply to part of the brain).
Zdravilo Clopidogrel 1A Pharma se lahko začne jemati nekaj dni po napadu do 35 dni po njem; bolnikom, ki so nedavno utrpeli ishemično kap (kap, ki jo povzroči pomanjkljiva oskrba določenega dela možganov s krvjo).
Clopidogrel 1A Pharma can be started between seven days and six months after the stroke;
Zdravilo Clopidogrel 1A Pharma se lahko začne jemati od sedem dni po napadu in do šest mesecev po njem;
Clopidogrel 1A Pharma can be used in patients who are having myocardial infarction with ‘ST segment elevation’ (an abnormal reading on the electrocardiogram or ECG) when the doctor thinks that they would benefit from the treatment.
Zdravilo Clopidogrel 1A Pharma se lahko uporablja pri bolnikih, ki so imeli srčni napad z „dvigom spojnice ST“ (nenormalni zapis na elektrokardiogramu ali EKG), če zdravnik meni, da bi jim zdravilo lahko pomagalo.
Clopidogrel 1A Pharma is a ‘generic medicine’.
Clopidogrel 1A Pharma je „generično zdravilo“.
Clopidogrel 1A Pharma is not intended for use in children or adolescents.
Zdravilo Klopidogrel 1A Pharma ni namenjeno za uporabo pri otrocih ali mladostnikih.
Clopidogrel 1A Pharma is unlikely to affect your ability to drive or to use machines.
Ni verjetno, da bi zdravilo Klopidogrel 1A Pharma vplivalo na vašo sposobnost za vožnjo ali upravljanje strojev.
Clopidogrel 1A Pharma may be taken with or without food.
Zdravilo Klopidogrel 1A Pharma lahko jemljete s hrano ali brez nje.
Clopidogrel Acino 75 mg film-coated tablets
Klopidogrel Acino 75 mg filmsko obložene tablete
Clopidogrel Acino can be started between a few days and 35 days after the attack; patients who have had a recent ischaemic stroke (stroke caused by failure of the blood supply to part of the brain).
Zdravilo Klopidogrel Acino se lahko začne jemati od nekaj dni po napadu do 35 dni po njem; ki so nedavno utrpeli ishemično kap (kap zaradi neoskrbe določenega dela možganov s krvjo).
Clopidogrel Acino clopidogrel
Klopidogrel Acino klopidogrel
Clopidogrel Acino contains hydrogenated castor oil
Zdravilo Klopidogrel Acino vsebuje hidrogenirano ricinusovo olje
Clopidogrel Acino contains hydrogenated castor oil which may cause stomach upset and diarrhoea.
Klopidogrel Acino vsebuje hidrogenirano ricinusovo olje, ki lahko razdraži želodec in povzroči drisko.
Clopidogrel Acino is a ‘generic medicine’.
Klopidogrel Acino je „generično zdravilo“.
Clopidogrel Acino is unlikely to affect your ability to drive or to use machines.
Ni verjetno, da bi zdravilo Klopidogrel Acino vplivalo na vašo sposobnost za vožnjo ali upravljanje strojev.
Clopidogrel Acino may be taken with or without food.
Zdravilo Klopidogrel Acino lahko jemljete s hrano ali brez nje.
Clopidogrel Acino Pharma 75 mg
Klopidogrel Acino Pharma 75 mg
Clopidogrel Acino Pharma 75 mg film-coated tablets
Klopidogrel Acino Pharma 75 mg filmsko obložene tablete
Clopidogrel Acino Pharma can be given to the following groups of patients: patients who have recently had a myocardial infarction (heart attack).
Zdravilo Clopidogrel Acino Pharma se lahko daje naslednjim skupinam bolnikov: bolnikom, ki so nedavno doživeli miokardni infarkt (srčni napad).
Clopidogrel Acino Pharma can be started between a few days and 35 days after the attack; patients who have had a recent ischaemic stroke (stroke caused by failure of the blood supply to part of the brain).
Zdravilo Clopidogrel Acino Pharma se lahko začne jemati od nekaj dni po napadu do 35 dni po njem; bolnikom, ki so nedavno utrpeli ishemično kap (kap, ki jo povzroči pomanjkljiva oskrba določenega dela možganov s krvjo).
Clopidogrel Acino Pharma can be started between seven days and six months after the stroke; patients with peripheral arterial disease (problems with blood flow in the arteries); The medicine can only be obtained with a prescription.
Zdravilo Clopidogrel Acino Pharma se lahko začne jemati od sedem dni po napadu do šest mesecev po njem; bolnikom s periferno arterijsko boleznijo (težavami s pretokom krvi v arterijah); Zdravilo se dobi samo na recept.
Clopidogrel Acino Pharma contains hydrogenated castor oil which may cause stomach upset or diarrhoea.
Zdravilo Klopidogrel Acino Pharma vsebuje hidrogenirano ricinusovo olje, ki lahko povzroči želodčne motnje ali drisko.
Clopidogrel Acino Pharma GmbH 75 mg
Klopidogrel Acino Pharma GmbH 75 mg
Clopidogrel Acino Pharma GmbH 75 mg film-coated tablets
Klopidogrel Acino Pharma GmbH 75 mg filmsko obložene tablete
Clopidogrel Acino Pharma GmbH can be given to the following groups of patients: patients who have recently had a myocardial infarction (heart attack).
Zdravilo Clopidogrel Acino Pharma GmbH se lahko daje naslednjim skupinam bolnikov: bolnikom, ki so nedavno doživeli miokardni infarkt (srčni napad).